Navigation Links
Dyadic International Extends All Debt Maturity Dates
Date:10/19/2013

JUPITER, Fla., Oct. 18, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic")(OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, biochemical, biopharmaceutical and industrial enzyme industries, announced today that it has entered into agreements with all of its outstanding promissory note holders to extend their maturity dates to January 1, 2015.  The convertible portion of the debt, representing $6.8 million of the total $8.2 million outstanding principal, may be prepaid by Dyadic at any time in whole or in part, without penalty, after March 31, 2014 with 30 days notice.  In all other respects, the terms and conditions of these promissory notes remain unchanged and in full force and effect.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "The extension of our debt provides Dyadic with greater flexibility by allowing us the option to call the convertible debt early."

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, biochemical, biopharmaceutical and industrial enzyme industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to levera
'/>"/>

SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dyadic International Reports Profitable 2012 Full Year Financial Results
2. Dyadic International To Announce Third Quarter 2012 Financial Results And Host Conference Call On Thursday, November 8, 2012
3. Dyadic Netherlands To Develop Enzymes For EU-Funded Research Consortium
4. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
5. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
6. CIVCO Names Darrell Newcombe as Vice President of International Sales for Radiation Oncology
7. Paul Kauffman of Accident Fund to Present on Identifying Risky Opioid Prescribing Patterns at 99th Annual International Association of Industrial Accident Boards & Commissions Conference
8. Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
9. Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimers Drug Discovery
10. WIKA Process Solutions, Deer Park, Texas Acquires Gayesco International.
11. PAREXEL International To Present At Robert Baird Healthcare Conference And Raymond James North American Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Calif. , July 29, 2015 /PRNewswire/ ... or the "Company"), the leading provider of ... sciences industry, serving markets including immunotherapies, stem ... manufacturers, animal health, and reproductive medicine, announced ... sale of common stock and warrants (the "Units") under ...
(Date:7/29/2015)... , July 29, 2015   KaloBios Pharmaceuticals, ... company focused on developing innovative therapies to benefit patients ... on oncology, announced today that the U.S. Food and ... drug (IND) application for KB003, an anti-GM-CSF monoclonal antibody ... that the IND is now active. The ...
(Date:7/29/2015)... RARITAN, N.J. , July 29, 2015  Ortho-Clinical ... for five assays under development. The assays address a ... acute kidney injury and cardiac troponin I. The scientific ... for Clinical Chemistry Annual Meeting to be held July ... .   "Ortho Clinical Diagnostics is emerging ...
Breaking Medicine Technology:Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3
... - Life Sciences Seasonal Appeal to Raise ... is changing the face of life science consulting, is delighted ... the unique opportunity for individuals from the life sciences industry ... from the pharmaceutical and venture capital industries. The ...
... Swick & Foti, LLC announces that the United ... Division approved the following announcement of a proposed ... publicly-traded securities of Acura Pharmaceuticals, Inc. (NASDAQ: ACUR): ... WHO PURCHASED OR OTHERWISE ACQUIRED THE PUBLICLY-TRADED SECURITIES ...
Cached Medicine Technology:Alacrita Launches Charity Auction of Executive One-to One Lunches with Senior Figures from the Pharmaceutical and Venture Capital Industries 2Alacrita Launches Charity Auction of Executive One-to One Lunches with Senior Figures from the Pharmaceutical and Venture Capital Industries 3Alacrita Launches Charity Auction of Executive One-to One Lunches with Senior Figures from the Pharmaceutical and Venture Capital Industries 4Kahn Swick & Foti, LLC Announces Class Action Settlement on Behalf of Purchasers of Publicly-Traded Securities of Acura Pharmaceuticals, Inc. -- ACUR 2Kahn Swick & Foti, LLC Announces Class Action Settlement on Behalf of Purchasers of Publicly-Traded Securities of Acura Pharmaceuticals, Inc. -- ACUR 3
(Date:7/30/2015)... ... 2015 , ... PeopleKeys, a company with over 30 years of experience in ... The webinar, the newest installment in their popular DISC for the Real World series, ... the Trainer webinar is intended for people interested in training others to use DISC ...
(Date:7/29/2015)... ... July 30, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, ... posters. The same poster art was used for the Charlotte Coliseum show a month ... and are classic boxing style concert posters. , They measure 22 x 28 ...
(Date:7/29/2015)... ... 2015 , ... According to data released today by the Centers for Medicare ... remain stable at $32.50, a figure far lower than was originally projected, the Pharmaceutical ... a bright spot in American health care. By offering an abundance of competing choices ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Sports fans ... to a visit by former players of the Detroit Lions, joined by A Forever ... 10th, 2015 Pro Bowl Wide Receiver Herman Moore, Pro Bowl Offensive Lineman Lomas Brown, ...
(Date:7/29/2015)... ... , ... This past week, CARE Surrogacy Center Mexico , took the ... the CARE extended family. , By shedding light on positive experiences — the ... gain a newfound perspective on surrogacy in Mexico. The center wholeheartedly believes in supporting ...
Breaking Medicine News(10 mins):Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2Health News:A Forever Recovery Holds Autograph Event with Former Detroit Lions at Cherry Festival 2Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 2Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 3
... of a new use for magnetic levitation, or "maglev," ... trains to float above the tracks. In ACS, bi-weekly ... describe putting maglev to use in an inexpensive sensor ... Whitesides and colleagues note that measurements of a substance,s ...
... in Spanish . Ensuring the optimum ... in prostate cancer treatment manages to control the illness in ... research undertaken at the University Hospital of Navarre and published ... the American Society of Brachytherapy. As is known, brachytherapy ...
... (June 23, 2010) Children who experience maltreatment ... likely to experience frequent headaches, including chronic migraine, as ... Headache Society,s 52nd Annual Scientific Meeting in Los Angeles ... Experiences (ACE) Study of 17,337 adult members of the ...
... Some 19 percent of soldiers returning from Iraq have ... While prevalence of migraine among the U.S. military ... quality in soldiers with chronic headaches including post-traumatic headache ... Army Medical Center in Tacoma, WA presenting at American ...
... having the most expensive health care system, the United ... countriesAustralia, Canada, Germany, the Netherlands, New Zealand, and the ... areas: quality, efficiency, access to care, equity and the ... a new Commonwealth Fund report. While there is room ...
... research professor in the department of physics at NJIT, ... Research Council (NRC) of the National Academies ( www.nationalacademies.org ... vehicles in the aftermath of Toyota,s large recalls. The ... and July 1, 2010 in Washington, DC, includes notable ...
Cached Medicine News:Health News:Optimizing brachytherapy dose on the same day as the implant can control prostate cancer 2Health News:US ranks last among 7 countries on health system performance 2Health News:US ranks last among 7 countries on health system performance 3Health News:NJIT professor heads panel studying sudden car acceleration 2
... Oxinium (oxidized zirconium) isn't a new implant. ... Smith & Nephew. Wear debris can be ... almost nil, addressing the needs of the ... are all improved. Initially, Oxinium is available ...
... anatomic knee system was ... minimize polyethylene wear between ... minimize contact stress associated ... achieve a well balanced ...
Simplified Design-Based on 15 Years of Experience...
... than a decade of in-vivo research, the ... study of knee kinematics through fluoroscopic review, ... analysis.,As a result of this exhaustive analysis ... in total knees, the 3DKnee implant provides ...
Medicine Products: